Background Hypercoagulability may contribute to COVID‐19 pathogenicity. The role of
anticoagulation (AC) at therapeutic (tAC) or prophylactic doses (pAC) is unclear. Objectives …

Background COVID-19 is associated with a prothrombotic state leading to adverse clinical
outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised …

Emerging evidence shows that severe coronavirus disease 2019 (COVID‐19) can be
complicated with coagulopathy, namely disseminated intravascular coagulation, which has …

Hypercoagulability is an increasingly recognized complication of SARS‐CoV‐2 infection. As
such, anticoagulation has become part and parcel of comprehensive COVID‐19 …

Background: Coagulopathy and thromboembolic events are common in Covid‐19 patients
and are poor prognostic factors. Controversy exists regarding the potential of …

Background Thromboprophylaxis of COVID-19 patients is a highly debated issue. We aimed
to compare the occurrence of thrombotic/ischemic events in COVID-19 patients with acute …

The incidence of venous thromboembolism (VTE) events in patients with COVID-19 treated
with a standard thromboprophylaxis dose of anticoagulants remains high. We conducted a …

Abstract Introduction Coronavirus disease 2019 (COVID-19) causes a hypercoagulable
state. Several autopsy studies have found microthrombi in pulmonary circulation. Methods In …

Background Since the body of evidence addressing the coagulation derangements caused
by Coronavirus disease (COVID-19) has been constantly growing, we investigated whether …

Abstract Purpose of Review We aim to provide a comprehensive analysis of
hypercoagulability in individuals affected by COVID-19. Our goal is to describe the …